Conference Description:

Unlocking Previously Inaccessible GPCR Drug Targets

As structural biology tools and screening technologies advance, the GPCR super family continues to be a hot area of drug discovery, with the potential to treat a plethora of diseases. For the first time ever, the GPCRs-Targeted Drug Discovery Summit Europe is coming to London, with the aim of overcoming pharmacology challenges and advancing the next wave of GPCR drug discovery.

This November, leading European biopharma experts and trail-blazing opinion leaders of academia are uniting under one roof at this inaugural Meeting to share data, discuss the latest advances in drug discovery. This Summit will deconvolute signalling bias, reveal novel targets for successful therapeutic interventions and fast-track structurally guided GPCR drug discovery across inflammatory, cardiovascular and metabolic indications and beyond.

Bringing together technical experts from Eli Lilly, AstraZenenca, Roche, ThirtyFiveBio, OMass Therapeutics and more, this Meeting aims to unlock previously undruggable targets, reveal the significance of genetic variants of GPCRs, showcase ground-breaking drug discovery tools and streamline the translation of small molecules and biologics into clinically successful therapies.

Join 70+ Senior Scientists, Heads and Directors of Drug Discovery, Biology, Chemistry and Pharmacology for 3 days of technical and data driven case studies and discussions, enabling you and your team to accelerate novel GPCR-targeted drug discovery.


URL:
Tickets: https://go.evvnt.com/2571866-1?pid=154
Time: 8:00 AM - 6:00 PM

Prices:
Conference Only - Industry Pricing: GBP 2599.00,
Conference + 1 Workshop - Industry Pricing: GBP 3098.00,
Conference + 2 Workshops - Industry Pricing: GBP 3597.00,
Conference Only - Academic Pricing: GBP 2199.00,
Conference + 1 Workshop - Academic Pricing: GBP 2598.00,
Conference + 2 Workshops - Academic Pricing: GBP 2997.00,
Conference Only - Service Provider Pricing: GBP 3099.00,
Conference + 1 Workshop - Service Provider Pricing: GBP 3698.00,
Conference + 2 Workshops - Service Provider Pricing: GBP 4297.00

Speakers: Alejandra Tomas Senior Lecturer Imperial College London, Arjan Snijder Director, Membrane Protein Sciences AstraZeneca, Arne Rufer Expert Scientist Roche, Barbara Cipriani VP, Head of Biology Pathios Therapeutics, Chris de Graaf GPCR SBDD/CADD Independent Expert, David Gloriam Professor University of Copenhagen, Frederick Westhorpe Director - Discovery Pharmacology COMPASS Pathways, Graeme Milligan Gardiner Professor, Biochemistry University of Glasgow, Irina Tikhonova Reader in Molecular Modelling Queen's University Belfast, Josselin Caradec Head of Biology ThirtyFiveBio, Lewis Vidler Senior Director - Structure Based Drug Design Eli Lilly and Co., Lies Dekeyzer Principal Scientist Confo Therapeutics, Michel Afargan Head Drug Development Starget Pharma, Miroslav Cik Senior Principal Research Scientist Abbvie, Oliver Hartley Vice President, Drug Discovery Orion Biotechnology, Richa Virmani Scientist Confo Therapeutics, Stephan Schann Chief Scientific Officer Domain Therapeutics, Steven Charlton Vice President, Pharmacology OMass Therapeutics, Thibaut Brugat Head of Research Portfolio Domain Therapeutics, Uwe Grether Expert Scientist Roche